All antagonists in hypertension, heart failure, and diabetic nephropathy: Focus on losartan

Current Medical Research and Opinion

Volumn 20, Issue 3, 2004, Pages 279-293

  Ferrario, Carlos ^a   Abdelhamed, Abdelhamed I ^a   Moore, Michael ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II antagonists; Heart failure; Hypertension; Nephropathy; Type 2 diabetes

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LACIDIPINE; LISINOPRIL; LOSARTAN; PLACEBO; SHORT ACTING DRUG; THIAZIDE DIURETIC AGENT; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNINDEXED DRUG; URIC ACID; VALSARTAN; ANGIOTENSIN RECEPTOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; REVIEW; SEXUAL DYSFUNCTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; SURVIVAL; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DIABETIC NEPHROPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; LOSARTAN; RECEPTORS, ANGIOTENSIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1542720652     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125003017     Document Type: Review

References (152)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
2. Cushman WC. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens (Greenwich) 2003;5:14-22
3. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi, G et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87
4. Lever AF, Beevers DG, Hole DJ, Isles CG, Meredith PA, Murray LS, et al. Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why? Clin Exp Hypertens 1999;21:553-62
5. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;23:888-92
6. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-44
7. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5
8. Sica DA, Douglas JG. The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens (Greenwich) 2001;3:244-51
9. Wright JT, Jr., Agodoa L, Contreras G, Greene T, Douglas JG, Lash J, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002;162:1636-43
10. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007
11. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
12. Alderman MH. ALLHAT and beyond. Am J Hypertens 2003;16:512-4
13. Flack JM, Nasser SA. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. Curr Hypertens Rep 2003;5:189-91
14. Beevers DG, Lee KW, Lip GY. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT? J Hum Hypertens 2003;17:367-72
15. Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003;16:407-15
16. Nilsson P. Conclusions in an Australian trial differ from those in the ALLHAT trial: ACE inhibitors are more effective than thiazides in elderly men with hypertension. Lakartidningen 2003;100:1118-20
17. Douglas JG, Agodoa L. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int 2003;(Suppl):S74-S76
18. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525-41
19. Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA 1970;214:301-10
20. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 1970;72:813-22
21. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6
22. Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up. J Hypertens 1996;14(Suppl):S43-S49
23. Diez J, Lopez B, Gonzalez A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 2001;16:328-35
24. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002;105:2512-7
25. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38:1222-6
26. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Ann Rev Physiol 1992;54:227-41
27. Segar JL, Dalshaug GB, Bedell KA, Smith OM, Scholz TD. Angiotensin II in cardiac pressure-overload hypertrophy in fetal sheep. Am J Physiol Regul Integr Comp Physiol 2001;281:R2037-R2047
28. Rockman HA, Wachhorst SP, Mao L, Ross J, Jr. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994;266:H2468-H2475
29. Arakawa K, Urata H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 2000;36:638-41
30. Urata H. Chymase in ischemic cardiovascular diseases. Nippon Rinsho 2003;61(Suppl 5):860-6.
31. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
32. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10:705-13
33. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10
34. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8
35. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
36. Tedesco MA, Ratti G, Aquino D, Limongelli G, Di Salvo G, Mennella S, et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998;12:505-10
37. Tedesco MA, Ratti G, Aquino D, Caccavale A, Acitorio M, Rocereto A, et al. The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension. Cardiologia 1998;43:53-9
38. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-42
39. Messerli FH. The LIFE study: the straw that should break the camel's back. Eur Heart J 2003;24:487-9
40. Messerli FH, Mehra MR. Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention for Endpoint Reduction in Hypertension [LIFE] Study). Am J Cardiol 2002;90:1133-4
41. [No author listed]. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7
42. [No author listed]. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57-66
43. Bansal BC, Agarwal AK, Rewari BB. Hypertension and cerebrovascular disease. J Indian Med Assoc 1999;97:226-32
44. Blann AD, Lip GY, Islim IF, Beevers DG. Evidence of platelet activation in hypertension. J Hum Hypertens 1997;11:607-9
45. Lip GY, Li-Saw-Hee FL. Does hypertension confer a hypercoagulable state? J Hypertens 1998;16:913-6
46. Nakano KK. An overview of stroke. Epidemiology, classification, risk factors, clinical aspects. Postgrad Med 1986;80:82-7
47. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475-82
48. Siragy HM. Angiotensin receptor blockers: how important is selectivity? Am J Hypertens 2002;15:1006-14
49. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033-9
50. Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999;17:869-72
51. Puig JG, Torres R, Ruilope LM. AT1 blockers and uric acid metabolism: are there relevant differences? J Hypertens 2002;20(Suppl 5):S29-31
52. Pantev E, Stenman E, Wackenfors A, Edvinsson L, Malmsjo M. Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries. Eur J Heart Fail 2002;4:699-705
53. Li P, Ferrario CM, Brosnihan KB. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997;281:1065-70
54. Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998;32:198-205
55. Lopez-Farre A, Sanchez dM, Monton M, Jimenez A, Lopez-Bloya A, Gomez J, et al. Angiotensin II AT(1) receptor antagonists and platelet activation. Nephrol Dial Transplant 2001;16(Suppl 1):45-9
56. Nunez A, Gomez J, Zalba LR, Monton M, Jimenez A, Velasco S, et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000;1:175-9
57. Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000;86:1188-92
58. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6
59. Doyle JC, Mottram DR, Stubbs H. Prescribing of ACE inhibitors for cardiovascular disorders in general practice. J Clin Pharm Ther 1998;23:133-6
60. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7-10
61. Konstam MA. Improving clinical outcomes with drug treatment in heart failure: what have trials taught? Am J Cardiol 2003;91:9D-14D
62. Sica DA. Pharmacotherapy in congestive heart failure. Prematurely terminated clinical trials and their application to cardiovascular medicine. Congest Heart Fail 2001;7:265-71
63. Moore MA. Drugs that interrupt the rennin-angiotensin system should be among the preferred initial drugs to treat hypertension. J Clin Hypertens (Greenwich) 2003;5:137-44
64. Moore MA. Improving the managed care of hypertension with angiotensin II antagonists. Am J Med Sci 2002;323:25-33
65. Cohn JN. Angiotensin receptor blockers and clinical trials in heart failure. Eur Heart J 2003;24:125-6
66. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52
67. Cowley AJ, Wiens BL, Segal R, Rich MW, Santanello NC, Dasbach EJ, et al. Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. Qual Life Res 2000;9:377-84
68. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7
69. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982;4:966-72
70. Rousseau MF, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488-93
71. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-7
72. Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol 1998;65:239-46
73. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
74. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64
75. Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997;13:1166-74
76. Greenberg BH. Role of angiotensin receptor blockers in heart failure: not yet RESOLVD. Circulation 1999;100:1032-4
77. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail 1999;5:276-82
78. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6
79. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71
80. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81
81. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66
82. Moore MA. Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive patient. J Clin Hypertens (Greenwich) 2001;3:37-44
83. Cohn JN. Lessons learned from the valsartan-heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. Am J Cardiol 2002;90:992-3
84. White HD. Candesartan and heart failure: the allure of CHARM. Lancet 2003;362:754-5
85. Kohzuki M, Yasujima M, Kanazawa M, Yoshida K, Fu LP, Obara K, et al. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 1995;13:97-103
86. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766-71
87. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62
88. Price DA, Hollenberg NK. Angiotensin receptor blockers in diabetic nephropathy. Curr Diab Rep 2001;1:267-74
89. Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001;16(Suppl 1):85-9
90. Remuzzi A, Fassi A, Bertani T, Perico N, Remuzzi G. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Am J Kidney Dis 1999;34:626-32
91. Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P, et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999;276:F457-F466
92. Border WA, Noble N. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semin Nephrol 2001;21:563-72
93. Ruoslahti E, Yamaguchi Y, Hildebrand A, Border WA. Extracellular matrix/growth factor interactions. Cold Spring Harb Symp Quant Biol 1992;57:309-15
94. de Jong PE, Navis G, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352-3
95. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001;60:228-34
96. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996;335:1636-42
97. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-6
98. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20:1576-81
99. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81
100. Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi G. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998;9:1948-55
101. Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 1993;267:657-63
102. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40-9
103. Ruggenenti P, Mosconi L, Sangalli F, Casiraghi F, Gambara V, Remuzzi G, et al. Glomerular size-selective dysfunction in N1DDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int 1999;55:984-94
104. del Castillo D, Campistol JM, Guirado L, Capdevilla L, Martinez JG, Pereira P, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998;68(Suppl):S135-9
105. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994;12(Suppl):S37-S42
106. Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998;13:3096-102
107. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
108. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
109. Lewis EJ, Hunsicker LG, Rodby RA. A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis 2001;38:S191-S194
110. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
111. Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 2002;15:123S-8S
112. Brenner BM, Cooper ME, Zeeuw DD, Grunfeld JP, Keane WF, Kurokawa K, et al. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000;1:328-35
113. Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000;15:487-97
114. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64
115. Lindholm LH, Dahlof B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH, et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003;362:619-20
116. [No author listed]. 2002 annual report: ESRD clinical performance measures project. Am J Kidney Dis 2003;42:1-96
117. Hostetter TH, Lising M. National kidney disease education program. J Am Soc Nephrol 2003;14:S114-S116
118. Jones CA. Hypertension and renal dysfunction: NHANES III. J Am Soc Nephrol 2003;14:S71-S75
119. Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, et al. Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation. Diabetes Care 2003;26:683-7
120. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24
121. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
122. Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens (Greenwich) 2002;4:424-32
123. Chan P, Liu JC, Tong YC, Chen YJ, Wang CC, Tomlinson B, et al. Effects of losartan on the sexual behavior of male rats. Pharmacology 1999;58:132-9
124. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997;157:1920-5
125. Alderman MH. Serum uric acid and cardiovascular disease risk. Ann Intern Med 2000;132:591
126. Breckenridge A. Hypertension and hyperuricaemia. Lancet 1966;1:15-8
127. Burnier M, Pechere-Bertschi A, Nussberger J, Waeber B, Brunner HR. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995;26:108-15
128. Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, Tanaka H, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002;41:793-7
129. Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268-71
130. Sasaki M, Fujimura A, Harada K, Sunaga K, Ebihara A. Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Pharmacol 1996;36:403-8
131. Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002;20:347
132. Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000;22:1186-203
133. Sayin T, Doven O, Akyurek O, Dincer I. Neutral effect of valsartan on serum uric acid and renal function tests. J Hum Hypertens 2001;15:435-6
134. Nikas S, Rizos E, Milionis H, Bairaktari E, Kalaitzidis R, Siamopoulos K, et al. The effects of the addition of losartan on uric acid metabolism in patients receiving indapamide. J Renin Angiotensin Aldosterone Syst 2000;1:289-91
135. Soffer BA, Wright JT, Jr., Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-7
136. 2-induced vasoconstriction in the rat hind-limb vascular bed in vivo. J Hypertens 2001;19:561-6
137. Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000;292:238-46
138. 2 receptor activation elicits organ-specific increases in microvascular permeability in the rat. Am J Physiol 1995;268:R366-R374
139. 2 analog. Arch Mal Coeur Vaiss 1994;87:971-4
140. 2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J Pharmacol Exp Ther 1994;268:747-52
141. 2 synthase inhibition. J Physiol Pharmacol 2000;51:715-22
142. Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770-6
143. Sadoshima J. Novel AT(1) receptor-independent functions of losartan. Circ Res 2002;90:754-6
144. Llisterri JL, Lozano Vidal JV, Aznar VJ, Argaya RM, Pol BC, Sanchez Zamorano MA, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001;321:336-41
145. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002;58:177-80
146. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001;14:27-31
147. Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone AC, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12:1130-4
148. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-81
149. Bloom BS. Daily regimen and compliance with treatment. BMJ 2001;323:647
150. Benedict CR. Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000;54:48-54
151. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418-26
152. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53